Sarepta Therapeutics (SRPT) Competitors $18.22 +0.03 (+0.14%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$18.22 0.00 (0.00%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. ELAN, LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, and PCVXShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Its Competitors Elanco Animal Health Legend Biotech TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Nuvalent Axsome Therapeutics Akero Therapeutics Vaxcyte Elanco Animal Health (NYSE:ELAN) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to ELAN or SRPT? In the previous week, Sarepta Therapeutics had 25 more articles in the media than Elanco Animal Health. MarketBeat recorded 36 mentions for Sarepta Therapeutics and 11 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.37 beat Sarepta Therapeutics' score of 0.22 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 25 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in ELAN or SRPT? 97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 0.9% of Elanco Animal Health shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, ELAN or SRPT? Elanco Animal Health has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElanco Animal Health$4.44B1.64$338M$0.7419.78Sarepta Therapeutics$1.90B0.94$235.24M-$2.69-6.77 Is ELAN or SRPT more profitable? Elanco Animal Health has a net margin of 8.43% compared to Sarepta Therapeutics' net margin of -11.12%. Elanco Animal Health's return on equity of 7.54% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elanco Animal Health8.43% 7.54% 3.57% Sarepta Therapeutics -11.12%-14.88%-5.12% Which has more risk and volatility, ELAN or SRPT? Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Do analysts recommend ELAN or SRPT? Elanco Animal Health currently has a consensus target price of $15.33, suggesting a potential upside of 4.74%. Sarepta Therapeutics has a consensus target price of $60.88, suggesting a potential upside of 234.20%. Given Sarepta Therapeutics' higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Sarepta Therapeutics 1 Sell rating(s) 12 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.44 SummaryElanco Animal Health beats Sarepta Therapeutics on 12 of the 16 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79B$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio-6.7721.4227.5020.21Price / Sales0.94281.76421.02118.64Price / Cash7.4942.7336.8958.07Price / Book1.147.518.045.67Net Income$235.24M-$55.05M$3.18B$249.13M7 Day Performance6.46%4.61%2.82%3.30%1 Month Performance-53.93%4.89%3.70%5.20%1 Year Performance-88.10%5.84%35.41%21.38% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.7339 of 5 stars$18.22+0.1%$60.88+234.2%-88.1%$1.79B$1.90B-6.771,372Trending NewsELANElanco Animal Health2.243 of 5 stars$13.36-0.7%$15.17+13.5%+3.6%$6.64B$4.43B18.059,000Analyst ForecastLEGNLegend Biotech3.1307 of 5 stars$33.85-0.4%$76.20+125.1%-23.0%$6.22B$627.24M-57.372,609Positive NewsAnalyst ForecastTGTXTG Therapeutics3.1637 of 5 stars$36.56+1.5%$40.80+11.6%+98.0%$5.80B$329M152.33290GRFSGrifols4.065 of 5 stars$8.37-4.6%$10.30+23.1%+36.7%$5.75B$7.81B7.1523,822LNTHLantheus4.2714 of 5 stars$80.81+2.0%$130.50+61.5%-0.4%$5.59B$1.53B22.96700TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.54B$516.72M0.00N/ANews CoverageAnalyst ForecastGap DownHigh Trading VolumeNUVLNuvalent3.73 of 5 stars$75.98+1.3%$115.50+52.0%+11.5%$5.46BN/A-17.3140Insider TradeAXSMAxsome Therapeutics4.7015 of 5 stars$101.65+1.0%$172.33+69.5%+31.3%$5.01B$385.69M-17.62380Trending NewsAnalyst ForecastAnalyst RevisionAKROAkero Therapeutics3.5687 of 5 stars$54.03-0.3%$82.50+52.7%+137.2%$4.31BN/A-27.7130Insider TradePCVXVaxcyte1.8185 of 5 stars$33.25+1.2%$136.50+310.5%-56.4%$4.29BN/A-8.33160News Coverage Related Companies and Tools Related Companies Elanco Animal Health Competitors Legend Biotech Competitors TG Therapeutics Competitors Grifols Competitors Lantheus Competitors Telix Pharmaceuticals Competitors Nuvalent Competitors Axsome Therapeutics Competitors Akero Therapeutics Competitors Vaxcyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
